<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00287573</url>
  </required_header>
  <id_info>
    <org_study_id>S5442</org_study_id>
    <secondary_id>TAXUS V ISR</secondary_id>
    <nct_id>NCT00287573</nct_id>
  </id_info>
  <brief_title>Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis</brief_title>
  <acronym>TAXUS V ISR</acronym>
  <official_title>A Prospective, Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stent in the Treatment of In-Stent Restenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the TAXUS Express2
      Paclitaxel-Eluting Coronary Stent System as compared to brachytherapy in patients
      experiencing in-stent restenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous approaches to in-stent restenosis (ISR) have included balloon angioplasty alone,
      rotational atherectomy, cutting balloon angioplasty, directional coronary atherectomy,
      excimer laser angioplasty, placement of a second stent or any combination thereof, and
      intra-coronary brachytherapy. Of these, only brachytherapy has been shown to reduce recurrent
      restenosis after PCI for ISR, - and is now considered the standard of care. Logistical
      considerations in establishing and maintaining a radiation program have limited the
      widespread availability of this modality. These considerations include the need for
      involvement of radiation oncologists, physicists, and safety officers; nuclear licensing
      requirements; need for increased shielding and safety training; equipment and procedural
      complexities; as well as increased procedural time and costs. Furthermore, recurrent ISR
      after brachytherapy may still occur. Stent based drug delivery for the treatment of ISR holds
      promise as a much simpler, safer and potentially more effective alternative to brachytherapy.

      This is a prospective, randomized (1:1), open-label, multicenter, safety and efficacy trial
      for the treatment of in-stent restenosis. The primary objective is to demonstrate a superior
      or non-inferior 9-month target vessel revascularization (TVR) rate for TAXUS-SR stent
      compared to intra-coronary brachytherapy (beta source).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Target Vessel Revascularization</measure>
    <time_frame>9 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite major adverse cardiac events (MACE) and the individual components of MACE</measure>
    <time_frame>assessed at discharge, 1, 4 and 9 months post index procedure and annually for 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF, defined as any ischemia-driven revascularization of the target vessel, MI related to the target vessel, or death related to the target vessel).</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical procedural success and technical success</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binary restenosis rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate outcomes and treatment of recurrent restenosis in the TAXUS stent arm</measure>
    <time_frame>5 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute lesion length</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reference Vessel Diameter (RVD)</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Lumen Diameter (MLD)</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent diameter stenosis (% DS)</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute gain</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss index</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of recurrent restenosis, including edge effect</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary aneurysm</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of potential safety issues.</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in neointimal volume from post procedure to follow-up</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MLD within the stent or area of brachytherapy</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum lumen area (MLA) within the stent or area of brachytherapy</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumen, plaque and vessel measurements at the treatment edges (outside of the stent or area of brachytherapy)</measure>
    <time_frame>9 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">488</enrollment>
  <condition>Coronary Restenosis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS Express2</intervention_name>
    <description>Paclitaxel-Eluting Coronary Stent System</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brachytherapy (beta source)</intervention_name>
    <description>Brachytherapy (beta source)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cumulative target lesion length is &lt;/= 46 mm (visual estimate).

          -  Reference vessel diameter (RVD) is &gt;/= 2.5 and &lt;/= 3.75 mm (visual estimate)

          -  Left ventricular ejection fraction (LVEF) is &gt;/= 25%

        Exclusion Criteria:

          -  Any previous or planned treatment with a non-study anti-restenotic drug-coated or
             drug-eluting coronary stent in the target vessel. (Note:previous or planned treatment
             with heparin or phosphorylcholine coated stents is acceptable, as long as, the
             procedure with the non-study stent meets the protocol defined criteria for non-target
             lesion interventions.)

          -  Previous or planned treatment with intra-coronary brachytherapy (gamma or beta source)
             in the target vessel

          -  Previous external radiotherapy to the heart or target vessel area

          -  Known genetic radiation sensitivity disorders (i.e. ataxia-telangiectasia, etc.)

          -  Side branch of the target lesion includes ostial narrowing &gt;/= 50% diameter stenosis
             (DS) and is &gt;/= 2.0 mm diameter

          -  Target lesion has been previously treated for ISR with the placement of a second
             stent(s), which covers &gt;/= 50% of the original stent length (a true &quot;stent sandwich&quot;)

          -  Target vessel is pre-treated with an unapproved device, directional or rotational
             coronary atherectomy, laser, or transluminal extraction catheter immediately prior to
             delivery of randomized treatment (stent placement or intra-coronary brachytherapy)

          -  Recent myocardial infarction (MI) (symptom onset &lt;/= 72 hours prior to randomization)

          -  CK-MB &gt;2x the local laboratory's upper limit of normal (ULN) (refers to a measured
             value on the day of the index procedure as drawn per protocol)

          -  Anticipated treatment with warfarin during any period in the 6 months post index
             procedure

          -  Anticipated treatment with paclitaxel, oral rapamycin or colchicine during any period
             in the 9 months post index procedure

          -  Planned use of both the study stent and a non-study stent (i.e., commercial stent) in
             the treatment of the target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg W. Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen G. Ellis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Medical Center Princeton</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Denver Cardiology</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912-6367</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospitals</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac &amp; Vascular Research Center of Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407-1195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center/Capital Cardiovascular Associates</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo General Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Carolina Cardiology Research Division/Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Clinical Trial Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Ohio Research, Ltd</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular Research Group</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Heart Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Austin Hospital/Capital Cardiovascular Specialists</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute in Cardiovascular Interventions</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook &amp; Women's College Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006 Mar 15;295(11):1253-63. Epub 2006 Mar 12.</citation>
    <PMID>16531618</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2006</study_first_submitted>
  <study_first_submitted_qc>February 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>August 5, 2010</last_update_submitted>
  <last_update_submitted_qc>August 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Marcie Clarkin</name_title>
    <organization>Boston Scientific</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Restenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

